ReviewFrontiers in public health2018
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Open access · goldAbstract readReview
In one paragraph
Review in Frontiers in public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
54.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 161 citations in OpenAlex.
- Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.BMC health services research · 2021Pooled it
- A model for the clinical management of the introduction of new medicines in a large University Hospital in Spain.Journal of pharmaceutical policy and practice · 2026Article
- A new way to read the price: measuring global affordability of selected NOACs.Frontiers in pharmacology · 2026Article
- Exploring community pharmacy manager/ pharmacist perceptions and responses to China's dual-channel policy for improving access and rational use of innovative drugs: a qualitative study.International journal of clinical pharmacy · 2025Article
- Pharmacoeconomics Education in Pharmacy Faculties: Status in Türkiye and Other Countries.Turkish journal of pharmaceutical sciences · 2025Article
- Cost-effectiveness of ceftolozane/tazobactam compared to meropenem in ventilator-associated pneumonia.Cost effectiveness and resource allocation : C/E · 2025Article
- Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- The early market access vehicle - An innovative demand-driven model to catalyse introduction of new optimal health products in low- and middle-income countries.Health policy OPEN · 2025Article
- Managing Pharmaceutical Costs in Health Systems: A Review of Affordability, Accessibility and Sustainability Strategies.Journal of market access & health policy · 2024Review
- Article
- Understanding medicine access strategies for innovator medicines registered in South Africa.BMC health services research · 2024Article
- Negotiating pricing and payment terms for insurance covered mHealth apps: a qualitative content analysis and taxonomy development based on a German experience.Health economics review · 2024Article
- Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin.European journal of clinical pharmacology · 2024Observational
- How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe : Better access to medicines through HTA.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Article
- MDMA for PTSD and beyond: a new paradigm brings hope.Frontiers in human neuroscience · 2024Article
- A Cross-Sectional Study Identifying Medication Adherence Technologies (MATech) in Sweden Using Behavior Change Techniques.Patient preference and adherence · 2024Article
- Drug supply management at first-level public health facilities: Case of Pyay District, Myanmar.PLOS global public health · 2024Article
- Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government.Applied health economics and health policy · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 20 institutions in 29 countries.
Brian GodmanStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Anna BucsicsMechanism of Coordinated Access to Orphan Medicinal Products (MoCA), Brussels, Belgium.
Patricia Vella BonannoStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Wija OortwijnEcorys, Rotterdam, Netherlands.
Celia C RotheDepartment of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland.
Alessandra FerrarioDivision of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, United States.
Simone BosselliEURORDIS-Rare Diseases Europe, Paris, France.
Andrew HillInstitute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
Antony P MartinHealth Economics Centre, University of Liverpool Management School, Liverpool, United Kingdom.
Steven SimoensKU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
Amanj KurdiStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Mohamed GadGlobal Health and Development Group, Imperial College, London, United Kingdom.
Jolanta GulbinovičDepartment of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania.
Angela TimoneyStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Tomasz BochenekDepartment of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland.
Ahmed SalemIQVIA, Brussels, Belgium.
Iris HoxhaDepartment of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania.
Robert SauermannHauptverband der Österreichischen Sozialversicherungsträger, Vienna, Austria.
Amos MasseleDepartment of Biomedical Sciences, Faculty of Medicine, University of Botswana, Gaborone, Botswana.
Augusto Alfonso GuerraDepartment of Social Pharmacy, College of Pharmacy, Federal University of Minas Gerais, Av. Presidente Antônio Carlos, Belo Horizonte, Brazil.
Guenka PetrovaDepartment of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Zornitsa MitkovaDepartment of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Gnosia AchniotouHealth Insurance Organisation (HIO), Nicosia, Cyprus.
Ott LaiusState Agency of Medicines, Tartu, Estonia.
Catherine SermetIRDES, Paris, France.
Gisbert SelkeWissenschaftliches Institut der AOK (WIdO), Berlin, Germany.
Vasileios KourafalosEOPYY-National Organization for the Provision of Healthcare Services, Athens, Greece.
John YfantopoulosSchool of Economics and Political Science, University of Athens, Athens, Greece.
Einar MagnussonDepartment of Health Services, Ministry of Health, Reykjavík, Iceland.
Roberta JoppiPharmaceutical Drug Department, Azienda Sanitaria Locale of Verona, Verona, Italy.
Margaret OlukaDepartment of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, Nairobi, Kenya.
Hye-Young KwonDivision of Biology and Public Health, Mokwon University, Daejeon, South Korea.
Arianit JakupiUBT - Higher Education Institute, Prishtina, Kosovo.
Francis KalemeeraDepartment of Pharmacology and Therapeutics, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia.
Joseph O FadareDepartment of Pharmacology and Therapeutics, Ekiti State University, Ado-Ekiti, Nigeria.
Oyvind MelienNorwegian Institute of Public Health, Oslo, Norway.
Maciej PomorskiAgency for Health Technology Assessment and Tariff System (AOTMiT), Warsaw, Poland.
Magdalene WladysiukHTA Consulting, Cracow, Poland.
Vanda Marković-PekovićMinistry of Health and Social Welfare, Banja Luka, Bosnia and Herzegovina.
Ileana MardarePublic Health and Management Department, Faculty of Medicine, "Carol Davila", University of Medicine and Pharmacy Bucharest, Bucharest, Romania.
Dmitry MeshkovNational Research Institution for Public Health, Moscow, Russia.
Tanja NovakovicZEM Solutions, Belgrade, Serbia.
Jurij FürstHealth Insurance Institute, Ljubljana, Slovenia.
Dominik TomekFaculty of Medicine, Slovak Medical University in Bratislava, Bratislava, Slovakia.
Corrine ZaraDrug Territorial Action Unit, Catalan Health Service, Barcelona, Spain.
Eduardo DiogeneVall d'Hebron University Hospital, Fundació Institut Català de Farmacologia, Barcelona, Spain.
Johanna C MeyerSchool of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
Rickard MalmströmDepartment of Medicine Solna, Karolinska Institutet and Clinical Pharmacology Karolinska University Hospital, Stockholm, Sweden.
Björn WettermarkDepartment of Medicine Solna, Karolinska Institutet and Clinical Pharmacology Karolinska University Hospital, Stockholm, Sweden.
Zinhle MatsebulaRaleigh Fitkin Memorial Hospital, Manzini, Swaziland.
Stephen CampbellDivision of Population Health, Health Services Research and Primary Care, Centre for Primary Care, University of Manchester, Manchester, United Kingdom.
Alan HaycoxHealth Economics Centre, University of Liverpool Management School, Liverpool, United Kingdom.
University of Liverpool · GBUniversity of Strathclyde · GBJagiellonian University · PLMedical University of Sofia · BGAdministration of Occupational Safety and Health · ISAgència de Qualitat i Avaluació Sanitàries de Catalunya · ESASL Roma · ITCarol Davila University of Medicine and Pharmacy · ROCRE Consulting (Poland) · PLEcorys (Netherlands) · NLEkiti State University · NGEuropean Organisation for Rare Diseases · FRHarvard University · USHealth Insurance Institute of Slovenia · SIImperial College London · GBInstitut de Recherche et de Documentation en Économie de la Santé · FRKarolinska Institutet · SEKarolinska University Hospital · SEKU Leuven · BEMokwon University · KR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
cancerfinancinghealth policymanaged entrynew modelsorphan diseasespharmaceuticals
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.